Chardan Capital Weighs in on Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Tourmaline Bio in a research report issued on Wednesday, April 23rd. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings of ($4.10) per share for the year. Chardan Capital has a "Buy" rating and a $70.00 price objective on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Chardan Capital also issued estimates for Tourmaline Bio's FY2026 earnings at ($4.73) EPS.

Other analysts have also recently issued reports about the stock. Wedbush lifted their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. HC Wainwright raised their target price on Tourmaline Bio from $49.00 to $50.00 and gave the company a "buy" rating in a report on Friday, March 14th. Finally, Lifesci Capital assumed coverage on Tourmaline Bio in a research report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price target for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tourmaline Bio currently has a consensus rating of "Buy" and a consensus price target of $49.33.

Tourmaline Bio Stock Down 2.5 %

Shares of NASDAQ:TRML opened at $16.89 on Monday. Tourmaline Bio has a 12-month low of $11.56 and a 12-month high of $29.79. The firm has a fifty day moving average of $14.77 and a two-hundred day moving average of $19.44. The firm has a market capitalization of $433.82 million, a P/E ratio of -5.99 and a beta of 2.14.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.05. The company had revenue of $0.04 million during the quarter.

Institutional Trading of Tourmaline Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Tourmaline Bio by 4.1% during the fourth quarter. Vanguard Group Inc. now owns 1,106,125 shares of the company's stock valued at $22,432,000 after acquiring an additional 43,652 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Tourmaline Bio during the fourth quarter valued at approximately $12,168,000. Geode Capital Management LLC raised its stake in shares of Tourmaline Bio by 6.4% in the third quarter. Geode Capital Management LLC now owns 482,078 shares of the company's stock valued at $12,396,000 after purchasing an additional 29,005 shares in the last quarter. Velan Capital Investment Management LP lifted its position in Tourmaline Bio by 28.0% in the fourth quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company's stock worth $8,595,000 after purchasing an additional 92,605 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in Tourmaline Bio by 69.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company's stock worth $8,515,000 after buying an additional 172,743 shares in the last quarter. 91.89% of the stock is currently owned by institutional investors and hedge funds.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.